Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCCNYSEARCA:IWM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$1.51-5.9%$2.80$1.48▼$8.29$106.84M2.991.40 million shs84,481 shsIWMiShares Russell 2000 ETF$197.58-1.0%$215.98$191.34▼$244.98$64.08B1.1928.44 million shs2.29 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics-8.57%-27.93%-40.96%-55.56%-80.42%IWMiShares Russell 2000 ETF-0.48%-4.49%-7.06%-9.72%-5.14%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCCCC4 Therapeutics2.5784 of 5 stars3.32.00.00.03.32.50.6IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.60Moderate Buy$12.50730.56% UpsideIWMiShares Russell 2000 ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CCCC and IWM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/14/2025CCCCC4 TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.58M3.00N/AN/A$4.07 per share0.37IWMiShares Russell 2000 ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$132.49M-$1.51N/AN/AN/A-313.35%-42.45%-27.55%5/6/2025 (Estimated)IWMiShares Russell 2000 ETFN/AN/A16.20∞N/AN/AN/AN/AN/ALatest CCCC and IWM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/2025Q4 2024CCCCC4 Therapeutics-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AIWMiShares Russell 2000 ETF$2.531.28%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A6.316.31IWMiShares Russell 2000 ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%IWMiShares Russell 2000 ETFN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.55%IWMiShares Russell 2000 ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics15070.99 million64.55 millionOptionableIWMiShares Russell 2000 ETFN/A323.20 millionN/ANot OptionableCCCC and IWM HeadlinesRecent News About These CompaniesRussell 2000 stumbles nearly 10% in Q1 – how biggest IWM ETF holdings faredMarch 31 at 7:39 PM | msn.com2 ETFs to Buy Hand Over Fist as Trump's “Liberation Day†NearsMarch 31 at 12:02 PM | 247wallst.com2 ETFs to Buy Hand Over Fist as Trump's “Liberation Day” NearsMarch 31 at 11:23 AM | 247wallst.comiShares Russell 2000 ETFMarch 26, 2025 | 247wallst.comLooking for Exposure to BBAI Stock? Try These Two ETFsMarch 18, 2025 | markets.businessinsider.comShould iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?March 13, 2025 | zacks.comIWM Crowded With SellersMarch 8, 2025 | nasdaq.comAre Small-Cap Stocks A Buy After Russell 2000 Correction?March 7, 2025 | benzinga.comIWM ETF: Russell 2000 crashes as fear and greed index tumblesFebruary 28, 2025 | invezz.comIWM: Buy The 10% Dip, Lower Rates A Bullish Factor With EPS Growth AheadFebruary 26, 2025 | seekingalpha.comSmall-Cap Surge: 3 Stocks Ready to Ride the Market Rotation (IWM)February 18, 2025 | marketbeat.comIWM: Small Caps Need Something Radical, Enter DOGEFebruary 18, 2025 | seekingalpha.comGeorge Soros Makes Significant Move with iShares Russell 2000 ETF in Q4 2024February 14, 2025 | gurufocus.comSoros buys Arthur J. Gallagher, boosts Accenture in Q4February 14, 2025 | markets.businessinsider.comWill Falling Bond Yields Send These 2 Small Caps Soaring? (IWM)February 13, 2025 | marketbeat.comBanking Stocks Lead the Week: Stronger Economy on the Horizon? (IWM)February 11, 2025 | marketbeat.comActively Managed TMSL Outperforms SMIDcap BenchmarksFebruary 7, 2025 | etftrends.comTrade War Heats Up: ETFs to Shield Your PortfolioFebruary 5, 2025 | zacks.comWinner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases 'Improved Execution' In Poultry, Says CEOFebruary 4, 2025 | benzinga.comWhat is the outlook of the iShares Russell 2000 (IWM) ETF?February 3, 2025 | invezz.comIWM, Small-Cap Stocks Face A Rocky Road AheadJanuary 24, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC and IWM Company DescriptionsC4 Therapeutics NASDAQ:CCCC$1.50 -0.10 (-5.94%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.iShares Russell 2000 ETF NYSEARCA:IWM$197.58 -1.91 (-0.96%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.iShares Russell 2000 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Russell 2000 Index (the Index). The Index is a float-adjusted capitalization weighted index that measures the performance of the small-capitalization sector of the United States equity market and includes securities issued by the approximately 2,000 smallest issuers in the Russell 3000 Index. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Index is a subset of the Russell 3000 Index, and serves as the underlying index for the Russell 2000 Growth and Value Index series. Component companies are adjusted for available float and must meet objective criteria for inclusion to the Index. The Fund's investment adviser is BlackRock Fund Advisors (BFA). More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? CAVA Group Stock: Time to Take the Dip on This Investment Trip? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
